Effect of Acute Bout of Exercise on Levels of PAHSA (ETAPA)
Primary Purpose
Insulin Sensitivity
Status
Recruiting
Phase
Not Applicable
Locations
Czechia
Study Type
Interventional
Intervention
Exercise
Fasting control
Sponsored by
About this trial
This is an interventional basic science trial for Insulin Sensitivity focused on measuring acute exercise, adipose tissue, insulin sensitivity, PAHSA, lipokinins
Eligibility Criteria
Inclusion Criteria:
- healthy young lean, young obese and elderly omnivorous men and women as defined by BMI, self-reported activity, self-reported medical history and self-reported diet assessment
- must be able to withstand repeated blood draws
- must be able to undergo abdominal fat biopsy
Exclusion Criteria:
- use of betablockers
- use of glucocorticoids
- use of non-steroidal anti-inflammatory drugs
- use of metformin in prediabetes
- use of psychiatric drugs such as selective serotonin reuptake inhibitors, serotonin and norepinephrine reuptake inhibitors, anticonvulsants and others
- oncologic malignancy
- chronic inflammatory or autoimmune diseases
- diabetes mellitus
- chronic ischemic heart disease
- cardiovascular and pulmonary disease
- renal and hepatological disease as assessed per biochemistry
- musculo-skeletal deviations limiting physical performance
- substance abuse
- other than omnivorous diet
Sites / Locations
- 3rd faculty of medicine, Charles UniversityRecruiting
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm Type
Experimental
Experimental
Experimental
Arm Label
Young lean men and women
Young obese men and women
Elderly men and women
Arm Description
25 to 40 y.o. participants with body mass index in range of 18.5 to 25
25 to 40 y.o. participants with body mass index in range of 30 to 45.
65 to 80 y.o. participants with body mass index in range of 18.5 to 30.
Outcomes
Primary Outcome Measures
Assessment of PAHSA levels and its changes in response to exercise and fasting in cohorts differing in age and fat mass
PAHSA levels [nmol/l] in serum sampled at pre-set time-points during control and intervention visits (including exercise session or plain fasting) and in subcutaneous abdominal white adipose tissue will be assessed by quantitative targeted lipidomic analysis.
Absolute and fold-change of PAHSA in plasma induced by experimental intervention (exercise, fasting) will be compared among individual cohorts.
Secondary Outcome Measures
Correlation of PAHSA levels with anthropometry and clinical characteristics
Basal levels of PAHSA and its changes in response to interventions will be correlated with anthropometric parameters (age, weight, fat mass) and parameters of physical fitness. Fat mass will be assessed by dual energy X-ray absorptiometry. Intercohort matching of obese and elderly subjects based on fat mass will be improved throughout the recruitment phase by utilization of fat mass assessment on two distinct certified bioimpedance instruments. Cohort physical fitness will be calculated as average from individual VO2max values obtained from maximum ergometry testing. Intercohort matching of young lean and young obese men and women will be based on age.
Correlation of PAHSA with various indexes of insulin sensitivity
Basal levels of PAHSA and its changes in response to interventions will be correlated with indices of muscle insulin sensitivity (MISI), hepatic insulin resistance (HIRI), adipose tissue insulin resistance (Adipo-IR) and homeostatic model assessment of insulin resistance (HOMA-IR). Values for measurement will be obtained by biochemical analysis of blood sampled during 5-point oral glucose tolerance test.
Full Information
NCT ID
NCT05572905
First Posted
September 26, 2022
Last Updated
October 5, 2022
Sponsor
Lenka Rossmeislova
Collaborators
Faculty Hospital Kralovske Vinohrady, Czech Academy of Sciences
1. Study Identification
Unique Protocol Identification Number
NCT05572905
Brief Title
Effect of Acute Bout of Exercise on Levels of PAHSA
Acronym
ETAPA
Official Title
Novel Approaches to Enhance Insulin-sensitizing Effects of Exercise: Targeting PAHSA Metabolism
Study Type
Interventional
2. Study Status
Record Verification Date
October 2022
Overall Recruitment Status
Recruiting
Study Start Date
May 1, 2021 (Actual)
Primary Completion Date
December 31, 2024 (Anticipated)
Study Completion Date
December 31, 2024 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Lenka Rossmeislova
Collaborators
Faculty Hospital Kralovske Vinohrady, Czech Academy of Sciences
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
Exercise represents an important tool in the prevention and treatment of metabolic disorders associated with obesity and aging, such as type 2 diabetes and cardiovascular disease. Besides skeletal muscle and its myokinins, the metabolic effects of exercise also rely on the induction of favorable changes in adipose tissue function. For example, adipose tissue is a source of lipokinins from the family of palmitic acid esters of hydroxy fatty acids (PAHSA), which have anti-inflammatory and insulin-sensitizing properties. We have recently shown that 4 months of exercise training increases PAHSA levels in adipose tissue and circulation. However, the mechanisms involved in the induction of PAHSA levels in response to exercise are unknown. The aim of the Effect of Acute Bout of Exercise on Levels of PAHSA (ETAPA) project is therefore to investigate the regulation of PAHSA metabolism in response to both acute and chronic exercise. To achieve this goal, we will employ state-of-the-art analytical methods to measure PAHSA levels in both adipose tissue and circulation of subjects of various ages and adiposity status. The main output of the ETAPA project will be the proof of principle regarding the important role of PAHSA lipokinins in exercise-induced enhancement of insulin sensitivity and the identification of potential drug targets that could be used to further improve PAHSA metabolism for the treatment of metabolic disorders associated with aging or obesity.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Insulin Sensitivity
Keywords
acute exercise, adipose tissue, insulin sensitivity, PAHSA, lipokinins
7. Study Design
Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
single groups assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
75 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Young lean men and women
Arm Type
Experimental
Arm Description
25 to 40 y.o. participants with body mass index in range of 18.5 to 25
Arm Title
Young obese men and women
Arm Type
Experimental
Arm Description
25 to 40 y.o. participants with body mass index in range of 30 to 45.
Arm Title
Elderly men and women
Arm Type
Experimental
Arm Description
65 to 80 y.o. participants with body mass index in range of 18.5 to 30.
Intervention Type
Other
Intervention Name(s)
Exercise
Intervention Description
Patients after overnight fast will cycle on ergo-meter for 60 minutes. No per-oral food intake will be allowed during the test. Level of the intensity of exercise will be determined as individual range of heart frequency (HF), oxygen consumption (VO2) and respiratory quotient (RQ) just bellow the aerobic threshold of the given participant (close to anticipated fatmax). These values will be obtained during maximal capacity stress test on cyclo-ergo-meter. This maximum stress test will be performed at least one week prior to the 60 minutes exercise to eliminate potential carry-over effect. Power output will be modulated during the 60 minutes of exercise to ensure keeping participants values of HF, RQ and VO2 in the given range. Blood will be sampled at 5 time points with interval of 30 minutes during the exercise (0, 30, 60, 90, 120) and 24 hours post-exercise.
Intervention Type
Other
Intervention Name(s)
Fasting control
Intervention Description
The same participants will be monitored while resting for 120 minutes in calm environment. No peroral food intake will be allowed during the test. Fasting control will take place at least one week apart of the exercise. Blood will be sampled at 5 timepoints with interval of 30 minutes during the exercise (0, 30, 60, 90, 120) and 24 hours post-control.
Primary Outcome Measure Information:
Title
Assessment of PAHSA levels and its changes in response to exercise and fasting in cohorts differing in age and fat mass
Description
PAHSA levels [nmol/l] in serum sampled at pre-set time-points during control and intervention visits (including exercise session or plain fasting) and in subcutaneous abdominal white adipose tissue will be assessed by quantitative targeted lipidomic analysis.
Absolute and fold-change of PAHSA in plasma induced by experimental intervention (exercise, fasting) will be compared among individual cohorts.
Time Frame
2 years
Secondary Outcome Measure Information:
Title
Correlation of PAHSA levels with anthropometry and clinical characteristics
Description
Basal levels of PAHSA and its changes in response to interventions will be correlated with anthropometric parameters (age, weight, fat mass) and parameters of physical fitness. Fat mass will be assessed by dual energy X-ray absorptiometry. Intercohort matching of obese and elderly subjects based on fat mass will be improved throughout the recruitment phase by utilization of fat mass assessment on two distinct certified bioimpedance instruments. Cohort physical fitness will be calculated as average from individual VO2max values obtained from maximum ergometry testing. Intercohort matching of young lean and young obese men and women will be based on age.
Time Frame
2 years
Title
Correlation of PAHSA with various indexes of insulin sensitivity
Description
Basal levels of PAHSA and its changes in response to interventions will be correlated with indices of muscle insulin sensitivity (MISI), hepatic insulin resistance (HIRI), adipose tissue insulin resistance (Adipo-IR) and homeostatic model assessment of insulin resistance (HOMA-IR). Values for measurement will be obtained by biochemical analysis of blood sampled during 5-point oral glucose tolerance test.
Time Frame
2 years
10. Eligibility
Sex
All
Minimum Age & Unit of Time
25 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
healthy young lean, young obese and elderly omnivorous men and women as defined by BMI, self-reported activity, self-reported medical history and self-reported diet assessment
must be able to withstand repeated blood draws
must be able to undergo abdominal fat biopsy
Exclusion Criteria:
use of betablockers
use of glucocorticoids
use of non-steroidal anti-inflammatory drugs
use of metformin in prediabetes
use of psychiatric drugs such as selective serotonin reuptake inhibitors, serotonin and norepinephrine reuptake inhibitors, anticonvulsants and others
oncologic malignancy
chronic inflammatory or autoimmune diseases
diabetes mellitus
chronic ischemic heart disease
cardiovascular and pulmonary disease
renal and hepatological disease as assessed per biochemistry
musculo-skeletal deviations limiting physical performance
substance abuse
other than omnivorous diet
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Lenka Rossmeislová, PhD
Phone
+420 26710 2211
Email
lenka.rossmeislova@lf3.cuni.cz
First Name & Middle Initial & Last Name or Official Title & Degree
Eva Krauzová, PhD
Phone
+420 26710 2324
Email
eva.krauzova@lf3.cuni.cz
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Lenka Rossmeislová, PhD
Organizational Affiliation
3rd Faculty of Medicine of Charles University in Prague
Official's Role
Principal Investigator
Facility Information:
Facility Name
3rd faculty of medicine, Charles University
City
Prague
ZIP/Postal Code
10000
Country
Czechia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Viktor Šebo, MD
Phone
+420267163031
Email
sebov@fnkv.cz
First Name & Middle Initial & Last Name & Degree
Eva Krauzová, PhD
Phone
+420267163031
Email
eva.krauzova@fnkv.cz
First Name & Middle Initial & Last Name & Degree
Rossmeislová Lenka, PhD
12. IPD Sharing Statement
Plan to Share IPD
No
Citations:
PubMed Identifier
29154942
Citation
Brezinova M, Kuda O, Hansikova J, Rombaldova M, Balas L, Bardova K, Durand T, Rossmeisl M, Cerna M, Stranak Z, Kopecky J. Levels of palmitic acid ester of hydroxystearic acid (PAHSA) are reduced in the breast milk of obese mothers. Biochim Biophys Acta Mol Cell Biol Lipids. 2018 Feb;1863(2):126-131. doi: 10.1016/j.bbalip.2017.11.004. Epub 2017 Nov 14.
Results Reference
result
PubMed Identifier
31806624
Citation
Paluchova V, Oseeva M, Brezinova M, Cajka T, Bardova K, Adamcova K, Zacek P, Brejchova K, Balas L, Chodounska H, Kudova E, Schreiber R, Zechner R, Durand T, Rossmeisl M, Abumrad NA, Kopecky J, Kuda O. Lipokine 5-PAHSA Is Regulated by Adipose Triglyceride Lipase and Primes Adipocytes for De Novo Lipogenesis in Mice. Diabetes. 2020 Mar;69(3):300-312. doi: 10.2337/db19-0494. Epub 2019 Dec 5.
Results Reference
result
Learn more about this trial
Effect of Acute Bout of Exercise on Levels of PAHSA
We'll reach out to this number within 24 hrs